New Sleep Apnea Treatment without CPAP

New sleep apnea treatment without CPAP now includes FDA-cleared implantable nerve stimulators, custom oral appliances, targeted airway surgery, and emerging medication options that did not exist a decade ago. According to the American Academy of Sleep Medicine, obstructive sleep apnea affects an estimated 30 million adults in the United States, yet roughly half of people prescribed CPAP therapy abandon it within the first year. This guide is for anyone who struggles with mask discomfort, cannot tolerate air pressure, or simply wants to understand every viable path beyond the CPAP machine. You will find detailed breakdowns of oral appliance therapy, hypoglossal nerve stimulation, surgical procedures, positional therapy, lifestyle modifications, myofunctional therapy, EPAP devices, and newer pharmacological approaches. Each section explains how the treatment works, who qualifies, what the evidence shows, and where it falls short, so you can build a personalized treatment plan with your provider.

Quick Answer

New sleep apnea treatment without CPAP includes oral appliances such as mandibular advancement devices, hypoglossal nerve stimulation implants like Inspire and Genio, upper airway surgery, positional therapy, EPAP devices, myofunctional therapy, weight management programs, and emerging medications including glucagon-like peptide 1 receptor agonists. The best alternative depends on sleep apnea severity, anatomy, body weight, and individual tolerance. A sleep study and clinical evaluation determine which option fits. Dumbo Health offers a $149 at-home sleep apnea test (in Florida, Texas, Virginia and Maryland) and a separate biomarker-driven longevity membership to help track how your treatment path is affecting your biology. Dumbo Health does not provide the alternative treatments described here.

Key Takeaways

• Oral appliance therapy using mandibular advancement devices reduces the apnea-hypopnea index by an average of roughly 50 percent in mild to moderate obstructive sleep apnea, according to published clinical data.
• Hypoglossal nerve stimulation with the Inspire device is FDA-cleared for moderate to severe obstructive sleep apnea and has shown a median 79 percent reduction in AHI at 5-year follow-up (Strollo PJ Jr et al.).
• Weight loss of 10 to 15 percent of body weight can reduce AHI by 50 percent or more in patients where obesity is a primary contributor, per NIH-funded research.
• Surgical options such as uvulopalatopharyngoplasty and maxillomandibular advancement target specific anatomical sites of airway obstruction, but success rates vary based on patient selection and drug-induced sleep endoscopy findings.
• Dumbo Health's Core membership at $0.99 a day tracks 51 sleep-longevity biomarkers twice a year, giving you a measurable way to monitor how sleep apnea treatment is affecting your biological aging trajectory.
• Not every CPAP alternative works for every severity level; central sleep apnea and complex sleep apnea often still require positive airway pressure therapy as the primary intervention.

Why So Many People Search for Sleep Apnea Treatment Beyond CPAP

CPAP therapy remains the gold-standard treatment for obstructive sleep apnea, but the gold standard only works when you actually use it. Continuous Positive Airway Pressure delivers a steady stream of pressurized air through a mask to keep the airway open during sleep. The problem is adherence. Medicare defines CPAP adherence as at least 4 hours per night on at least 70 percent of nights, and multiple studies have shown that 30 to 50 percent of patients fail to meet that threshold.

Mask discomfort is the most commonly reported reason for CPAP abandonment. Poor mask fit causes air leaks, nasal dryness, skin irritation, and claustrophobia. Some patients experience aerophagia, which is swallowing air that leads to bloating and discomfort. Others find that the noise of PAP machines disrupts their partner's sleep or that traveling with the device is impractical.

The clinical stakes of untreated sleep apnea extend far beyond snoring. Untreated obstructive sleep apnea is associated with a two- to threefold increase in cardiovascular risk, including heart disease, stroke, and atrial fibrillation, according to the National Heart, Lung, and Blood Institute. Sleep apnea also disrupts sleep architecture, reducing the time spent in restorative deep sleep and REM sleep, which accelerates measurable markers of biological aging. This is precisely why Dumbo Health frames sleep as a longevity input, not just a clinical symptom. When your sleep is fragmenting 30 or more times per hour, the downstream effects on inflammation, metabolic health, and hormone regulation show up in your blood biomarkers.

The good news: the landscape of CPAP alternatives has expanded dramatically. Treatments that were experimental 10 years ago are now FDA-cleared, insurance-reimbursable, and backed by multi-year outcome data.

KEY TAKEAWAY: CPAP therapy is effective when used consistently, but high abandonment rates driven by mask discomfort, air pressure intolerance, and lifestyle friction have fueled demand for clinically validated alternatives.

Understanding what each alternative can and cannot do starts with knowing how your airway obstruction actually occurs.

How Airway Obstruction Causes Obstructive Sleep Apnea

Obstructive sleep apnea occurs when the soft tissue in the upper airway collapses during sleep, blocking airflow despite ongoing breathing effort. The airway is not a rigid tube. It is surrounded by muscles and tissue that relax during sleep, and in people with certain anatomical or physiological risk factors, that relaxation causes partial or complete obstruction.

Where the Airway Collapses

The most common sites of airway obstruction include the soft palate, the base of the tongue, the lateral pharyngeal wall muscles, and the tissue around the tonsils. In many patients, the collapse happens at multiple levels simultaneously. This multi-level anatomy is one reason why no single alternative treatment works for everyone.

A drug-induced sleep endoscopy, also called sleep endoscopy, allows sleep specialists and an ENT specialist (otolaryngologist) to visualize exactly where the airway collapses under sedation. This information is critical for choosing the right surgical or device-based intervention.

The Apnea-Hypopnea Index Explained

The apnea-hypopnea index, or AHI, is the primary metric used to diagnose and classify sleep apnea severity. AHI measures the number of apneas (complete airflow cessation) and hypopneas (partial airflow reduction) per hour of sleep.

• Mild obstructive sleep apnea: AHI 5 to 14 events per hour
• Moderate obstructive sleep apnea: AHI 15 to 29 events per hour
• Severe obstructive sleep apnea: AHI 30 or more events per hour

The oxygen desaturation index (ODI) measures how often blood oxygen drops by 3 to 4 percent or more per hour, adding another layer of clinical data. Both AHI and ODI are captured during a sleep study, whether conducted in a lab or through an at-home sleep test.

Dumbo Health's FDA-cleared at-home sleep apnea test captures these metrics for $149, with physician diagnosis typically delivered within 48 hours. That diagnostic clarity is the first step toward selecting the right CPAP alternative, because the treatment that works for an AHI of 12 is very different from the treatment needed for an AHI of 45.

DID YOU KNOW: The Wisconsin Sleep Cohort Study, one of the longest-running population-based sleep studies, found that the prevalence of moderate to severe sleep apnea increased by 14 to 55 percent over two decades, largely driven by rising obesity rates.

KEY TAKEAWAY: Obstructive sleep apnea results from airway collapse at one or more anatomical sites, and the AHI score determines severity, which directly shapes which CPAP alternatives are appropriate.

The most widely prescribed CPAP alternative is an oral appliance, and its evidence base has grown substantially.

Oral Appliance Therapy: Mandibular Advancement Devices and Tongue Retaining Devices

Oral appliance therapy is the most common CPAP alternative for mild to moderate obstructive sleep apnea. An oral appliance is a custom-fitted dental device worn during sleep that repositions the jaw or tongue to maintain an open airway.

How Mandibular Advancement Devices Work

A mandibular advancement device, commonly abbreviated as MAD, is the most prescribed type of oral appliance. Mandibular advancement devices work by holding the lower jaw (mandible) in a slightly forward position during sleep. This forward positioning pulls the tongue base away from the back of the throat, increases the airway diameter, and reduces airway obstruction.

MADs are custom-fitted by a dentist trained in dental sleep medicine. Custom-fitted mouthguards are fabricated from dental impressions or digital scans and are adjustable, meaning the degree of mandibular advancement can be titrated to find the position that best reduces AHI without causing excessive jaw strain.

Over-the-counter mouth guards marketed for snoring are not the same as prescription mandibular advancement devices. Generic mouth guards lack the precision fit, adjustability, and clinical monitoring that make prescription MADs effective for treating diagnosed sleep apnea.

How Tongue Retaining Devices Differ

A tongue retaining device, also called a tongue-retaining device, works differently from a MAD. Instead of advancing the jaw, a tongue retaining device uses suction to hold the tongue in a forward position, preventing it from falling back and blocking the airway. Tongue retaining devices may suit patients who have dental conditions, such as insufficient teeth or temporomandibular joint disorders, that make mandibular advancement uncomfortable or impractical.

What the Evidence Shows

The American Academy of Sleep Medicine recommends oral appliance therapy as a first-line treatment for mild to moderate obstructive sleep apnea and as a second-line option for patients with severe sleep apnea who cannot tolerate CPAP. Clinical trials consistently show that MADs reduce AHI by approximately 50 percent on average, with higher success rates in patients who have supine-dependent or positional sleep apnea.

Adherence rates for oral appliances tend to be higher than for CPAP. Published studies report nightly use rates of 77 to 90 percent at one year, compared with 40 to 60 percent for CPAP. Higher adherence partially offsets the fact that CPAP achieves greater AHI reduction on any given night when used.

Limitations of Oral Appliance Therapy

• Less effective for severe obstructive sleep apnea with AHI above 30
• May cause jaw soreness, tooth movement, or bite changes over time
• Requires ongoing dental follow-up to monitor occlusal changes
• Not appropriate for patients with central sleep apnea
• Adverse effects include excessive salivation and temporary morning bite discomfort

Who Oral Appliance Therapy Is Best For

Oral appliance therapy is best suited for adults with mild to moderate obstructive sleep apnea (AHI 5 to 29), patients who have failed CPAP due to mask discomfort or air pressure intolerance, and people who travel frequently and need a portable, mask-free approach. Sleep specialists typically recommend a follow-up sleep study after oral appliance fitting to confirm that AHI has been adequately reduced.

KEY TAKEAWAY: Mandibular advancement devices are the most evidence-backed oral appliance for sleep apnea, offering high adherence and meaningful AHI reduction for mild to moderate cases, though they are less effective for severe obstructive sleep apnea.

For patients with moderate to severe disease who cannot use CPAP or oral appliances, implantable nerve stimulation offers a different mechanism entirely.

Hypoglossal Nerve Stimulation: Inspire, Genio, and the Science of Upper Airway Stimulation

Hypoglossal nerve stimulation is an implantable sleep apnea solution that treats obstructive sleep apnea by electrically stimulating the hypoglossal nerve, the nerve that controls tongue movement, to prevent the tongue from collapsing backward during sleep. Upper airway stimulation represents the most significant advancement in non-CPAP sleep apnea treatment in the past decade.

How Inspire Therapy Works

The Inspire device is the most widely implanted hypoglossal nerve stimulation system in the United States. Inspire therapy uses a small generator implanted under the skin of the upper chest, a sensing lead that detects breathing patterns, and a stimulation lead wrapped around the hypoglossal nerve. When the sensor detects an inhalation, the generator sends a mild electrical impulse to the hypoglossal nerve, which causes the tongue and other airway muscles to stiffen and move forward, keeping the airway open.

The Inspire device is activated by the patient using a small handheld remote before sleep. Patients typically turn on the device at bedtime and turn it off upon waking. The implant requires a brief outpatient surgical procedure, and patients generally begin using the device about a month after implantation. The system was developed through research involving Strollo PJ Jr, Soose RJ, Maurer JT, and other investigators, with pivotal trial data published in the New England Journal of Medicine.

The Genio System by Nyxoah

The Genio system, developed by Nyxoah, is a newer FDA-cleared hypoglossal nerve stimulation device that differs from Inspire in several ways. The Genio system stimulates both hypoglossal nerves bilaterally using a single small implant placed under the chin. It does not require a chest-implanted generator or a breathing sensor lead. Instead, the patient wears an external activation chip on a disposable adhesive patch placed under the chin during sleep.

The bilateral stimulation approach of the Genio system may offer advantages for patients whose airway obstruction involves both tongue-related and other soft tissue collapse patterns. Clinical data published by Magaña LC and others have shown significant AHI reductions with the Genio system, though long-term follow-up data is still maturing compared to the Inspire device's multi-year track record.

Eligibility Criteria for Hypoglossal Nerve Stimulation

Not everyone qualifies for upper airway stimulation. The Food and Drug Administration clearance for these devices specifies certain criteria:

• Diagnosis of moderate to severe obstructive sleep apnea (AHI typically 15 to 65)
• Inability to use or benefit from CPAP therapy
• Body mass index generally below 35 (Inspire) or below 32 (Genio)
• No concentric collapse pattern at the soft palate level, confirmed by drug-induced sleep endoscopy
• Age 18 or older (22 or older for some indications)
• Not indicated for central sleep apnea or complex sleep apnea

A drug-induced sleep endoscopy is required before implantation to confirm the pattern of airway obstruction. If the soft palate collapses concentrically (closing in a circular pattern), the device is unlikely to be effective because tongue advancement alone cannot overcome that collapse geometry.

Long-Term Outcome Data

Five-year data from the STAR trial (Strollo PJ Jr et al.) showed that Inspire therapy produced a median 79 percent reduction in AHI and a 74 percent reduction in oxygen desaturation index. Patient-reported outcomes showed significant reductions in daytime sleepiness as measured by the Epworth Sleepiness Scale and improvements in overall sleep quality. These results have been consistent across multiple follow-up studies and real-world registries.

DID YOU KNOW: According to Henry Ford Health, hypoglossal nerve stimulation has been performed on more than 80,000 patients since FDA clearance, making it the fastest-growing surgical sleep apnea treatment category.

Costs and Insurance Coverage

Inspire therapy is covered by most major insurance plans and Medicare for patients who meet clinical criteria; coverage for the newer Genio system is still developing. Out-of-pocket costs vary based on insurance coverage, deductibles, and whether the procedure is performed at an in-network facility.

Insurance pre-authorization typically requires documentation of CPAP failure, a qualifying AHI range, and drug-induced sleep endoscopy results showing a non-concentric collapse pattern.

KEY TAKEAWAY: Hypoglossal nerve stimulation with devices like Inspire and Genio offers durable AHI reductions for moderate to severe obstructive sleep apnea in patients who cannot tolerate CPAP, but eligibility depends on BMI, collapse pattern, and confirmed CPAP failure.

Some patients may not meet implant criteria or may prefer less invasive options, which is where surgical and procedural interventions come in.

Surgical and Procedural Treatments for Sleep Apnea

Upper airway surgery for sleep apnea targets the specific anatomical structures causing airway obstruction. Sleep surgery is typically considered when CPAP, oral appliances, and other conservative treatments have been tried and failed, or when a clear anatomical cause of obstruction can be identified and corrected.

Uvulopalatopharyngoplasty

Uvulopalatopharyngoplasty, commonly known as UPPP, is the most frequently performed sleep surgery. UPPP removes or repositions excess tissue from the soft palate, uvula, and lateral pharyngeal walls to widen the airway at the level of the throat. Success rates for UPPP as a standalone procedure vary widely, with reported AHI reduction ranging from 33 to 50 percent. Success is highest when the soft palate is the primary or sole site of obstruction.

UPPP has a recovery period of 2 to 3 weeks, during which patients typically experience significant throat pain, difficulty swallowing, and temporary changes in voice quality. Rare but serious adverse effects include velopharyngeal insufficiency, a condition where the soft palate can no longer fully close against the back of the throat, leading to nasal regurgitation of liquids. Velopharyngeal stenosis, or scarring that narrows the airway, is another uncommon but recognized complication.

Barbed Reposition Pharyngoplasty and Lateral Pharyngoplasty

Barbed reposition pharyngoplasty is a newer technique that uses barbed sutures to reposition the lateral pharyngeal wall muscles and soft palate tissue, creating a wider airway without removing as much tissue as traditional UPPP. Lateral pharyngoplasty similarly focuses on restructuring the side walls of the throat. Both procedures aim to reduce the tissue-removal complications associated with older techniques while maintaining or improving efficacy.

Early clinical data suggests that barbed reposition pharyngoplasty may achieve AHI reduction rates comparable to or better than traditional UPPP, with lower rates of postoperative pain and velopharyngeal complications.

Maxillomandibular Advancement

Maxillomandibular advancement, or MMA, is the most effective surgical treatment for obstructive sleep apnea, with reported success rates of 85 to 100 percent in appropriately selected patients. MMA moves both the upper and lower jaw bones forward, permanently enlarging the airway space behind the tongue and soft palate.

MMA is a major surgical procedure requiring 4 to 6 weeks of recovery. The jaw bones are cut, repositioned forward by 10 to 12 millimeters on average, and fixed in place with titanium plates. MMA changes facial structure, which some patients view positively and others consider a drawback. The procedure is typically reserved for patients with severe obstructive sleep apnea who have failed all other treatments, or for patients with documented skeletal deficiency contributing to airway obstruction.

Tonsillectomy, Septoplasty, and Turbinate Reduction

Tonsillectomy removes enlarged tonsils that contribute to airway obstruction. In adults, tonsillectomy alone rarely cures obstructive sleep apnea but can be an important component of a multi-level surgical approach. In children, tonsillectomy combined with adenoidectomy is the first-line treatment for pediatric obstructive sleep apnea.

Septoplasty corrects a deviated nasal septum that restricts nasal airflow, and turbinate reduction reduces the size of swollen nasal turbinates. These nasal procedures rarely cure sleep apnea on their own, but improving nasal airflow can improve CPAP tolerance, oral appliance effectiveness, and overall sleep quality.

The Role of Drug-Induced Sleep Endoscopy in Surgical Planning

Drug-induced sleep endoscopy is a procedure where a flexible endoscope is passed through the nose while the patient is under light sedation to simulate natural sleep. The otolaryngologist (ENT specialist) observes the dynamic pattern of airway collapse in real time, identifying the exact sites and severity of obstruction.

Sleep endoscopy findings directly influence the surgical plan. A patient with isolated soft palate collapse may benefit from UPPP alone, while a patient with multi-level collapse involving the tongue base, soft palate, and lateral walls may need a combination of procedures or may be better suited for hypoglossal nerve stimulation or maxillomandibular advancement.

Bariatric Surgery as an Indirect Sleep Apnea Treatment

Bariatric surgery is not a sleep surgery in the traditional sense, but it is one of the most effective interventions for sleep apnea in patients with severe obesity. Obesity is the single strongest modifiable risk factor for obstructive sleep apnea. According to the NIH, approximately 60 to 70 percent of people with obstructive sleep apnea are overweight or obese, and fat deposits around the upper airway directly contribute to airway obstruction.

Bariatric surgery typically produces weight loss of 20 to 30 percent of total body weight, and multiple studies show that AHI decreases significantly after surgery. However, bariatric surgery does not cure sleep apnea in all patients, particularly those with significant anatomical contributors beyond obesity. Follow-up sleep studies after weight stabilization are recommended to assess residual disease.

KEY TAKEAWAY: Surgical options range from tissue-removal procedures like UPPP to skeletal repositioning with maxillomandibular advancement, and the right procedure depends on drug-induced sleep endoscopy findings that map the exact sites of airway collapse.

Beyond surgery and devices, several non-invasive and behavioral approaches can reduce sleep apnea severity, sometimes enough to avoid more aggressive treatments.

Positional Therapy, EPAP Devices, and Other Non-Invasive Alternatives

Several non-invasive alternatives to CPAP address specific contributors to airway obstruction, including sleep position, expiratory resistance, and oropharyngeal muscle tone. These options work best for mild to moderate obstructive sleep apnea or as adjuncts to primary treatment.

Positional Therapy and the Tennis Ball Technique

Positional therapy is a treatment approach for patients whose sleep apnea is significantly worse when sleeping on their back (supine position). Positional sleep apnea is defined as an AHI that is at least twice as high in the supine sleep position compared to non-supine positions. An estimated 50 to 60 percent of people with obstructive sleep apnea have a significant positional component.

The simplest form of positional sleep therapy is the tennis ball technique, in which a tennis ball or similar object is attached to the back of a sleep shirt to discourage supine sleeping. More sophisticated positional therapy devices include vibrating chest-worn sensors that detect supine position and deliver a gentle vibration prompting the sleeper to turn onto their side without waking fully.

Positional therapy alone may be sufficient for patients with mild positional sleep apnea. For moderate to severe cases, positional therapy is typically used alongside oral appliances or other interventions.

EPAP Devices: Provent Therapy and Bongo Rx

Expiratory Positive Airway Pressure (EPAP) devices create resistance during exhalation, which generates a back-pressure that splints the airway open through the breathing cycle. Unlike CPAP, EPAP devices do not require electricity, a machine, or a traditional mask.

Provent Therapy is an EPAP device that uses small adhesive valves placed over each nostril. The valves allow unrestricted inhalation but create resistance during exhalation, maintaining positive airway pressure without a machine. Bongo Rx is a reusable nasal EPAP device with a similar mechanism but uses a silicone nasal interface instead of disposable adhesive valves.

EPAP devices are FDA-cleared for obstructive sleep apnea and work best for mild to moderate cases. Clinical trials of Provent Therapy showed a mean AHI reduction of approximately 43 percent, with better results in patients with lower baseline AHI. EPAP devices are not effective for central sleep apnea or for patients who primarily breathe through their mouth during sleep.

Myofunctional Therapy

Myofunctional therapy is a set of exercises that strengthen the tongue, throat, and facial muscles involved in maintaining airway patency during sleep. Myofunctional therapy targets the same muscles that become lax and allow airway collapse: the tongue, soft palate, and lateral pharyngeal wall muscles.

A meta-analysis published on PubMed found that myofunctional therapy reduced AHI by approximately 50 percent in adults with obstructive sleep apnea and reduced snoring frequency and intensity. The exercises typically include tongue positioning drills, soft palate elevation exercises, and lip and cheek strengthening routines performed for 15 to 20 minutes daily.

Myofunctional therapy requires consistent daily practice over several months to produce results. It is most effective as a complement to other treatments rather than as a standalone therapy for moderate to severe disease.

Daytime Tongue Stimulation: eXciteOSA

eXciteOSA is an FDA-cleared electric muscle stimulation device that delivers mild electrical currents to the tongue during waking hours, typically for 20 minutes per day over a 6-week initial training period. The device strengthens the tongue muscles so they are less likely to collapse during sleep. eXciteOSA is classified among tongue stimulators and electric muscle stimulation devices, and it differs from implantable nerve-stimulation devices like Inspire because it is external and used during the day rather than during sleep.

Clinical data for eXciteOSA shows reduction in snoring and mild obstructive sleep apnea, but it is not currently indicated for moderate to severe disease.

Checklist: Deciding If a Non-Invasive Alternative May Work for You

• Confirm your AHI and severity classification with a sleep study (Dumbo Health offers an at-home sleep apnea test for $149 in Florida, Texas, Virginia and Maryland)
• Determine whether your sleep apnea has a significant positional component
• Assess whether you primarily breathe through your nose or mouth during sleep
• Review any dental conditions that might affect oral appliance candidacy

• Take the free Dumbo Health sleep quiz to understand how your sleep patterns connect to biological aging
• Discuss myofunctional therapy with a trained orofacial myologist or speech-language pathologist
• Evaluate whether your BMI is a primary contributor to your sleep apnea
• Ask your provider about a trial period with an EPAP device if you have mild to moderate disease
• Consider whether you need a portable solution for travel or daily use

KEY TAKEAWAY: Non-invasive alternatives like positional therapy, EPAP devices, and myofunctional therapy can meaningfully reduce AHI in mild to moderate cases and often work best as part of a multi-modal treatment plan.

Lifestyle modifications, particularly weight management, represent another powerful lever for reducing sleep apnea severity.

Lifestyle Modifications and Weight Management as Sleep Apnea Treatment

Weight loss is the single most impactful lifestyle modification for obstructive sleep apnea in patients where obesity is a contributing factor. According to the NIH, a 10 percent reduction in body weight can reduce AHI by approximately 26 to 50 percent, and in some cases, mild sleep apnea resolves entirely with sustained weight loss.

How Obesity Drives Airway Obstruction

Obesity contributes to sleep apnea through multiple mechanisms. Excess fat deposits around the upper airway narrow the pharyngeal space. Abdominal obesity reduces lung volume, which decreases the downward traction on the upper airway and makes it more collapsible. Metabolic inflammation associated with obesity can also cause swelling in airway tissue.

Body mass index (BMI) above 30 is a major risk factor, but neck circumference above 17 inches in men or 16 inches in women is an even more specific predictor of obstructive sleep apnea risk. Not all people with obesity have sleep apnea, and not all people with sleep apnea are obese, but the overlap is substantial enough that weight management is a cornerstone of any comprehensive treatment plan.

Glucagon-Like Peptide 1 Receptor Agonists and Emerging Medications

Glucagon-like peptide 1 receptor agonists, a class of medications originally developed for type 2 diabetes, have shown significant promise for sleep apnea treatment through their potent weight loss effects. A randomized trial published in 2024 showed that tirzepatide reduced AHI by 51 to 63 percent in participants with obesity and moderate to severe obstructive sleep apnea, largely through weight reduction averaging 18 to 20 percent of body weight.

In December 2024, the FDA approved tirzepatide (Zepbound) for moderate to severe obstructive sleep apnea in adults with obesity, making it the first drug approved for sleep apnea itself. Sleep specialists are increasingly incorporating these medications into personalized treatment plans for patients with obesity-related obstructive sleep apnea.

Other medications are being investigated. AD109 (Apnimed) is a once-nightly pill combining aroxybutynin and atomoxetine that targets airway muscle tone. After two positive phase 3 trials, its application was accepted by the FDA in July 2026, with a target decision date of February 28, 2027. It is still investigational, not FDA-approved, and has not been shown to work as well as CPAP. Sulthiame, an epilepsy drug, is in earlier (phase 2) study for sleep apnea.

Other Lifestyle Changes That Affect Sleep Apnea

• Alcohol avoidance within 3 to 4 hours of bedtime reduces airway muscle relaxation during sleep
• Smoking cessation reduces upper airway inflammation and fluid retention
• Consistent sleep habits, including regular bedtimes, improve overall sleep architecture
• Reducing sedative use and discussing medication alternatives with providers can minimize airway muscle depression
• Nasal saline rinses or allergy management improve nasal airflow for patients with rhinitis

Step-by-Step Process: Getting Started With a Weight Management Strategy for Sleep Apnea

1. Complete a diagnostic sleep study to establish your baseline AHI and oxygen desaturation index. Dumbo Health's at-home sleep apnea test delivers results with physician interpretation within 48 hours for $149 (available in Florida, Texas, Virginia and Maryland).
2. Measure your current BMI, neck circumference, and waist circumference to quantify how much body composition is contributing to your airway obstruction.
3. Discuss pharmacological weight management options, including glucagon-like peptide 1 receptor agonists, with your primary care provider or sleep specialist.
4. Enroll in a structured nutrition and exercise program targeting 10 to 15 percent total body weight loss over 6 to 12 months.
5. Track your sleep-related biomarkers alongside weight changes. Dumbo Health's Core membership tests 51 sleep-longevity biomarkers twice a year for $0.99 a day, providing objective data on how metabolic improvements translate into reduced biological aging.
6. Repeat your sleep study after reaching your weight loss target to reassess AHI and determine whether additional treatment is still needed.
7. Maintain your weight loss and continue longitudinal biomarker tracking, since AHI tends to rebound if weight is regained.

After completing these steps, you will have a clear, data-driven view of how much your weight contributed to your sleep apnea and whether further treatment is required.

KEY TAKEAWAY: Weight loss of 10 to 15 percent can halve AHI scores in obesity-related sleep apnea, and emerging GLP-1 receptor agonists are accelerating the viability of pharmacological weight management as a bona fide sleep apnea intervention.

While these treatments address the airway itself, there is a broader question most patients overlook: how untreated or undertreated sleep apnea silently ages their bodies at a cellular level.

Sleep Apnea, Biological Aging, and Why Biomarker Tracking Changes the Treatment Equation

Untreated obstructive sleep apnea accelerates biological aging through chronic intermittent hypoxia, systemic inflammation, and disrupted circadian rhythm signaling. This is the connection that most sleep apnea treatment discussions miss entirely. Fixing the airway is necessary but not sufficient if you are not measuring the downstream damage.

How Sleep Apnea Accelerates Biological Age

Each apnea event triggers a cycle of oxygen desaturation followed by reoxygenation, which generates oxidative stress. According to the National Institute on Aging, oxidative stress is one of the primary mechanisms driving cellular aging. Repeated nightly oxygen desaturation, sometimes hundreds of times per night in severe cases, creates a chronic inflammatory state reflected in elevated biomarkers including high-sensitivity C-reactive protein (hs-CRP), interleukin-6, and tumor necrosis factor-alpha.

Sleep apnea also suppresses deep sleep and disrupts sleep architecture. Deep sleep is when growth hormone secretion peaks, cellular repair occurs, and memory consolidation happens. When sleep architecture is fragmented by repeated arousals, these restorative processes are curtailed. Over months and years, this translates into measurable changes in metabolic markers (HbA1c, fasting insulin), cardiovascular markers (ApoB, NT-proBNP), hormonal markers (cortisol, DHEA-S, testosterone), and kidney function (GFR).

Biological age, which measures how old your body appears based on biomarker data and epigenetic patterns, can diverge significantly from chronological age in people with untreated sleep disorders. A 45-year-old with severe untreated sleep apnea may have the biomarker profile of someone a decade older.

SleepLongevityAge: Quantifying the Connection

Dumbo Health's proprietary SleepLongevityAge metric was designed to quantify exactly this relationship. SleepLongevityAge is built from blood biomarkers combined with optional wearable data from devices like Oura, Whoop, or Garmin, and reviewed by physicians. The metric provides a single score that tells you whether your sleep is accelerating or slowing your biological aging process.

This matters for anyone pursuing sleep apnea treatment because it gives you an objective way to measure whether your chosen treatment is actually producing systemic health improvement, not just reducing your AHI number. A patient whose AHI drops from 30 to 5 on an oral appliance but whose inflammatory markers and metabolic biomarkers remain elevated still has work to do.

Dumbo Health's Core plan tests 51 sleep-longevity biomarkers twice a year for early members at $0.99 a day, billed annually at $365 a year. The Concierge plan includes 103 biomarkers, a dedicated sleep physician with 24/7 access, a personal sleep coach, and all add-on specialty packs for $300 a month for early members. Both plans are HSA and FSA eligible, require no insurance, and involve no prior authorizations.

Real-World Examples

A 52-year-old executive with a family history of cardiovascular disease completes a home sleep apnea test through Dumbo Health and receives a diagnosis of moderate obstructive sleep apnea with an AHI of 22. He opts for a mandibular advancement device because he travels frequently and cannot manage CPAP equipment across time zones. After 3 months on the MAD, his follow-up sleep study shows AHI dropped to 8. But his Dumbo Health biomarker panel reveals persistently elevated hs-CRP and ApoB, prompting his physician to investigate residual inflammation and add a statin. Without biomarker tracking, he would have assumed his problem was solved.

A 38-year-old wearable user notices her Oura ring consistently flags fragmented deep sleep and elevated resting heart rate. She assumes it is stress-related, but the Dumbo Health sleep quiz suggests she may have undiagnosed mild sleep apnea. Her at-home sleep test confirms an AHI of 11. She begins positional therapy and myofunctional exercises, and her 6-month biomarker retest shows improved HbA1c and cortisol levels, with her SleepLongevityAge dropping by 2.4 years.

A 60-year-old with severe obstructive sleep apnea (AHI 48) tried CPAP for 8 months but averaged only 2.5 hours of nightly use due to claustrophobia and mask discomfort. His sleep specialist recommends drug-induced sleep endoscopy, which shows anteroposterior tongue base collapse without concentric palatal collapse, making him eligible for Inspire therapy. Post-implantation, his AHI drops to 6. His Dumbo Health Concierge membership provides longitudinal biomarker tracking showing progressive improvement in his testosterone, GFR, and inflammatory markers over the following year.

AHI reduction alone does not guarantee improved biological health outcomes. Biomarker tracking provides the objective verification that your sleep apnea treatment is translating into reduced systemic inflammation, improved metabolic function, and slower biological aging.

KEY TAKEAWAY: Sleep apnea accelerates biological aging through chronic intermittent hypoxia and sleep architecture disruption, and biomarker tracking through platforms like Dumbo Health's SleepLongevityAge provides the objective data needed to verify that treatment is producing real health improvement.

Understanding the full spectrum of options also means knowing which alternatives have limited evidence or significant constraints.

Limitations and Risks: When CPAP Alternatives May Not Be the Right Choice

No single CPAP alternative is universally effective, and honest acknowledgment of limitations is essential for making an informed treatment decision. The right alternative depends on your severity classification, anatomy, body composition, and the specific cause of your airway obstruction.

When Oral Appliances Are Insufficient

Oral appliance therapy with mandibular advancement devices is less reliable for severe obstructive sleep apnea. Patients with an AHI above 30 may see some reduction in events but often do not achieve the target AHI below 5 that constitutes clinical success. Additionally, patients with fewer than 6 healthy teeth, severe temporomandibular joint dysfunction, or advanced periodontal disease may not be candidates for MADs.

Long-term use of mandibular advancement devices can cause permanent changes in dental occlusion (how the teeth fit together), including anterior open bite and mandibular prognathism. These adverse effects are typically gradual and may take years to become clinically significant, but they require ongoing dental monitoring.

When Hypoglossal Nerve Stimulation Does Not Apply

Hypoglossal nerve stimulation requires specific anatomical eligibility confirmed by drug-induced sleep endoscopy. Patients with concentric collapse of the soft palate are not candidates. BMI cutoffs (generally below 32 to 35 depending on the device) exclude many patients for whom obesity is the primary driver of their sleep apnea. The implantable device also requires MRI-conditional protocols, meaning future MRI scans require coordination with the device manufacturer.

Patients with central sleep apnea or complex sleep apnea are not candidates for hypoglossal nerve stimulation because the mechanism of their apnea does not involve upper airway obstruction.

When Surgery Carries Unacceptable Risk

Upper airway surgery success rates are highly variable and depend heavily on patient selection. UPPP as a standalone procedure has a surgical success rate (defined as AHI reduction below 20 and by at least 50 percent) of only 40 to 60 percent when patient selection is not guided by drug-induced sleep endoscopy. Maxillomandibular advancement has the highest success rate but is the most invasive option, with risks including numbness, jaw stiffness, and altered facial appearance.

Post-surgical complications such as velopharyngeal insufficiency, velopharyngeal stenosis, and temporary dysphagia are uncommon but consequential. Patients should discuss realistic outcome expectations and revision surgery rates with their otolaryngologist.

When Lifestyle Modifications Are Not Enough on Their Own

Weight loss is effective but slow, and many patients need interim treatment while pursuing weight management goals. Patients with anatomically driven sleep apnea (such as large tonsils, retrognathic jaw, or naturally narrow airway) may not see meaningful AHI improvement from weight loss alone.

Sleep habits and positional therapy have floor effects. Once AHI reaches moderate or severe levels, behavioral interventions alone rarely achieve adequate control.

The Central and Complex Sleep Apnea Challenge

Central sleep apnea and complex sleep apnea (treatment-emergent central sleep apnea that appears after CPAP is initiated) present unique challenges. Most CPAP alternatives, including oral appliances, hypoglossal nerve stimulation, and airway surgery, target upper airway obstruction and are ineffective for central apnea. Central sleep apnea is typically managed with adaptive servo-ventilation or bilevel positive airway pressure (BiPAP), which are still positive airway pressure therapies.

Patients who suspect they may have central or complex sleep apnea should ensure their sleep study includes analysis of central versus obstructive event classification. Ask your doctor whether your test reports central events; if central sleep apnea is suspected, an in-lab study may be needed to confirm it. Dumbo Health's at-home sleep test is available in Florida, Texas, Virginia and Maryland, with physician diagnosis typically within 48 hours.

KEY TAKEAWAY: Every CPAP alternative has specific eligibility criteria and failure modes, and the most important step is accurate diagnosis, including sleep study data and, when surgery or implants are considered, drug-induced sleep endoscopy to map the anatomy of airway collapse.

With these limitations in mind, a side-by-side comparison helps clarify which approach fits which situation.

Comparing CPAP Alternatives: A Decision Framework

Choosing the right sleep apnea treatment without CPAP depends on your AHI severity, BMI, anatomy, budget, and lifestyle. The following structured comparison covers the most common alternatives across the attributes that matter most for decision-making.

Best For Mild Obstructive Sleep Apnea (AHI 5 to 14)

• Oral Appliance Therapy (MAD): first-line alternative with strong adherence and portability
• Positional Therapy: effective if AHI is significantly worse in the supine position
• EPAP Devices (Provent, Bongo Rx): suitable for nose breathers who want a mask-free approach
• Myofunctional Therapy: helpful adjunct, especially for mild snoring and mild AHI
• eXciteOSA: daytime tongue stimulation cleared for mild OSA and snoring

Best For Moderate to Severe Obstructive Sleep Apnea (AHI 15 and Above)

• Hypoglossal Nerve Stimulation (Inspire, Genio): FDA-cleared for AHI 15 to 65, strongest long-term data for CPAP non-adherent patients
• Maxillomandibular Advancement Surgery: highest surgical success rate, reserved for severe or refractory cases
• Multi-Level Airway Surgery (UPPP combined with tongue base procedure): appropriate when drug-induced sleep endoscopy shows multi-site collapse
• Weight Loss and GLP-1 Medications: most effective when obesity is the primary contributor
• Oral Appliance Therapy: second-line for moderate to severe when CPAP and surgery are not options

Portability

• Oral Appliance: highly portable, fits in a small case
• EPAP Device: extremely portable, no power needed
• Positional Therapy Device: portable, battery-powered
• Hypoglossal Nerve Stimulation: fully implanted, nothing external during sleep (Inspire) or small adhesive patch (Genio)
• CPAP (for reference): least portable, requires power source and water for humidifier

Insurance Coverage Likelihood

• CPAP: covered by nearly all plans
• Oral Appliance: covered by most medical and some dental plans
• Hypoglossal Nerve Stimulation: covered by most major plans and Medicare with pre-authorization
• Upper Airway Surgery: generally covered with documented medical necessity
• EPAP Devices: coverage varies, and they are often paid out of pocket
• GLP-1 Medications: insurance coverage for obesity indication varies widely

Estimated Time to Full Therapeutic Effect

• CPAP: immediate on first use
• Oral Appliance: 2 to 6 weeks including titration
• Hypoglossal Nerve Stimulation: 1 to 2 months post-implantation (activation and optimization period)
• Upper Airway Surgery: 3 to 6 months for swelling resolution and tissue healing
• Weight Loss: 6 to 12 months for clinically meaningful AHI impact
• Myofunctional Therapy: 3 to 6 months with daily practice

For most patients with mild to moderate obstructive sleep apnea who want a non-surgical approach, oral appliance therapy offers the best balance of efficacy, adherence, and convenience. For moderate to severe patients who have genuinely failed CPAP, hypoglossal nerve stimulation provides the strongest evidence-backed surgical alternative. Regardless of which treatment path you choose, pairing it with biomarker monitoring gives you objective proof that the treatment is working beyond the AHI number alone. Dumbo Health's sleep longevity membership offers longitudinal biomarker tracking with physician review alongside whatever treatment you and your doctor choose.

KEY TAKEAWAY: The best CPAP alternative is the one that matches your specific AHI severity, anatomical collapse pattern, body composition, and lifestyle requirements, and the most reliable way to verify its effectiveness is through objective biomarker monitoring over time.

Before committing to a treatment path, it helps to clear up the most persistent misconceptions about CPAP alternatives.

Common Myths About Sleep Apnea Treatment Without CPAP Debunked

MYTH: Oral appliances are just fancy mouth guards and do not really treat sleep apnea.

FACT: Custom-fitted mandibular advancement devices prescribed through dental sleep medicine are FDA-cleared medical devices, not over-the-counter mouth guards. The American Academy of Sleep Medicine recommends MADs as a first-line treatment for mild to moderate obstructive sleep apnea, and clinical trials demonstrate average AHI reductions of approximately 50 percent with adherence rates significantly higher than CPAP.

MYTH: Inspire therapy is experimental and does not have long-term data.

FACT: The Inspire device received FDA clearance in 2014 and has been implanted in over 80,000 patients worldwide. Five-year follow-up data from the STAR trial (Strollo PJ Jr et al.) showed sustained median AHI reductions of 79 percent. Inspire therapy is covered by most major insurers and Medicare. The Genio system by Nyxoah offers a newer bilateral stimulation approach with its own growing evidence base.

MYTH: Losing weight will definitely cure my sleep apnea.

FACT: Weight loss reduces AHI substantially in obesity-related obstructive sleep apnea, with NIH-funded research showing that 10 percent weight loss can reduce AHI by 26 to 50 percent. However, weight loss alone does not cure sleep apnea in all patients, particularly those with anatomical contributors such as enlarged tonsils, retrognathic jaw, or a naturally narrow airway. A follow-up sleep study after weight loss is essential to determine whether residual disease requires treatment.

MYTH: If I snore, I definitely have sleep apnea, and any anti-snoring product will fix it.

FACT: Snoring is a common symptom of obstructive sleep apnea, but not everyone who snores has sleep apnea, and not every anti-snoring product treats the underlying apnea events. A diagnostic sleep study measuring AHI and oxygen desaturation is required to differentiate benign snoring from clinically significant sleep apnea. Anti-snoring sprays, generic mouth guards, and pillow products do not treat obstructive sleep apnea and can create a false sense of security.

MYTH: You only need treatment if your sleep apnea is severe.

FACT: Even mild obstructive sleep apnea (AHI 5 to 14) is associated with increased cardiovascular risk, impaired cognitive function, and accelerated biological aging when left untreated over years. The National Heart, Lung, and Blood Institute notes that chronic intermittent hypoxia at any severity level can drive inflammation, metabolic dysfunction, and vascular damage. Treatment decisions should factor in symptoms, daytime sleepiness, comorbidities, and biomarker data, not AHI alone.

KEY TAKEAWAY: The most common myths about CPAP alternatives either underestimate the evidence behind approved treatments or overestimate the effectiveness of unvalidated consumer products, and a diagnostic sleep study remains the non-negotiable first step.

Choosing Your Path: A Practical Summary for Patients and Providers

Selecting the right sleep apnea treatment without CPAP is not a single decision. It is a clinical process that starts with accurate diagnosis, incorporates anatomical assessment and biomarker data, and evolves as you track outcomes over time.

Sleep specialists, otolaryngologists, dental sleep medicine providers, and primary care physicians each bring different expertise to the treatment plan. The most successful outcomes consistently come from a personalized treatment plan that matches the specific mechanism of your airway obstruction to the right intervention.

If you are a patient reading this article because you cannot tolerate CPAP, here is the most important takeaway: alternatives exist that are FDA-cleared, evidence-backed, and covered by insurance in most cases. But the worst decision is no decision. Untreated sleep apnea does not plateau. It progressively damages your cardiovascular system, metabolic health, cognitive function, and biological age.

Dumbo Health offers sleep apnea testing and CPAP care in Florida, Texas, Virginia and Maryland, and a separate sleep longevity membership for biomarker tracking. Start with the free sleep quiz to see how your current sleep patterns may be affecting your biological aging. If you need a sleep apnea diagnosis, the $149 at-home sleep test provides physician-interpreted results within 48 hours, with no insurance required. And if you want ongoing visibility into how your treatment is changing your health at the biomarker level, the Core plan at $0.99 a day for early members gives you 51 sleep-longevity biomarkers tested twice a year, with early-member pricing locked for life for the first 500 members.

The goal is not just sleeping soundly. It is sleeping in a way that slows biological aging rather than accelerating it.

Frequently Asked Questions About Sleep Apnea Treatment Without CPAP

What are the main alternatives to CPAP for treating sleep apnea?

Several medically validated alternatives to CPAP therapy exist for treating obstructive sleep apnea. The most commonly used options include oral appliances such as mandibular advancement devices, hypoglossal nerve stimulation therapy (such as the Inspire device), upper airway surgery, positional therapy, expiratory positive airway pressure devices, myofunctional therapy, and lifestyle modifications such as weight loss and sleep hygiene changes. The right alternative depends on the severity of your apnea, your anatomy, your overall health, and how well you tolerate different treatments. A sleep specialist can help determine which option is appropriate for your situation.

What is the best treatment for sleep apnea without CPAP?

There is no single best treatment for sleep apnea without CPAP because the most effective option depends on the individual. For mild to moderate obstructive sleep apnea, oral appliance therapy using a mandibular advancement device is often recommended. For moderate to severe OSA in people who cannot tolerate CPAP, hypoglossal nerve stimulation such as Inspire therapy has shown strong clinical results. Upper airway surgery may benefit some patients with specific anatomical causes of obstruction. A sleep specialist will typically use your apnea-hypopnea index, anatomy, sleep study results, and symptom profile to guide the treatment plan.

Can sleep apnea be cured without CPAP?

Sleep apnea cannot always be permanently cured, but it can often be effectively managed or, in some cases, significantly reduced without CPAP therapy. Weight loss through lifestyle changes or bariatric surgery can meaningfully lower apnea severity in people with obesity-related obstructive sleep apnea. Upper airway surgery and maxillomandibular advancement can produce durable results for carefully selected patients. Hypoglossal nerve stimulation has shown sustained improvement over several years in clinical studies. However, most treatments manage the condition rather than eliminate it entirely, and ongoing monitoring is recommended. A sleep specialist can help you understand what level of improvement may be realistic for your case.

How do I sleep with sleep apnea without CPAP?

If you have obstructive sleep apnea and cannot tolerate CPAP, several practical strategies may help reduce symptoms. Sleeping on your side rather than your back is one of the most accessible starting points, since the supine position promotes airway collapse in many people. Positional therapy devices and the tennis ball technique are commonly used to encourage side sleeping. An oral appliance worn during sleep can help keep the jaw and tongue positioned to maintain a more open airway. Weight loss, avoiding alcohol before bed, and treating nasal congestion can also reduce nighttime breathing interruptions. A sleep specialist should guide which approach is appropriate for your level of airway obstruction.

Is Inspire therapy better than CPAP for sleep apnea?

For patients who qualify and cannot tolerate CPAP, Inspire therapy can be a highly effective alternative. Inspire is an implantable upper airway stimulation device that delivers mild electrical impulses to the hypoglossal nerve, keeping the tongue and airway muscles active during sleep. Clinical studies have shown significant reductions in the apnea-hypopnea index and improvements in oxygen desaturation index and daytime sleepiness scores in eligible patients. However, Inspire therapy requires surgery, has specific eligibility criteria, is not suitable for central sleep apnea or severe obesity in many cases, and carries its own risks. Whether it is better than CPAP depends on individual anatomy, severity, and treatment goals, and this decision should be made with a sleep physician.

Can central sleep apnea be treated without a CPAP machine?

Central sleep apnea, where breathing pauses occur because the brain fails to send the correct signals to the breathing muscles rather than because of an airway obstruction, is generally harder to manage without PAP therapy than obstructive sleep apnea. Bilevel positive airway pressure, also called BiPAP, and adaptive servo-ventilation are commonly used for central sleep apnea, and these are still forms of PAP therapy. Addressing underlying causes such as heart disease, medication side effects, or high altitude exposure may reduce central apnea events. Oxygen therapy is sometimes considered. Because central sleep apnea has different mechanisms than obstructive sleep apnea, treatment decisions should always be guided by a sleep specialist and, where relevant, a cardiologist.

Are oral appliances effective for severe sleep apnea?

Oral appliances, particularly mandibular advancement devices, are most effective for mild to moderate obstructive sleep apnea and are generally considered a first-line alternative to CPAP for these severities. For severe obstructive sleep apnea, oral appliance therapy is less predictably effective and may not reduce the apnea-hypopnea index to safe levels in all patients. The American Academy of Sleep Medicine notes that oral appliances are a recommended treatment option for patients who prefer them over CPAP or who cannot tolerate CPAP, including some with severe OSA, but follow-up sleep testing is important to confirm adequate treatment response. A sleep specialist or dental sleep medicine provider should fit and monitor any oral appliance.

Why do some people seek CPAP alternatives?

People seek alternatives to CPAP for a range of reasons. The most commonly reported include mask discomfort and pressure sensitivity, difficulty exhaling against continuous airway pressure, feelings of claustrophobia, skin irritation, dry mouth or nasal dryness, noise disturbing a bed partner, and difficulty travelling with the device. Some patients find that even with adjustments to mask fit, nasal pillows, or pressure settings, they cannot achieve consistent nightly use. Long-term CPAP adherence remains a significant challenge across the sleep medicine field. If you are struggling with CPAP therapy, speaking with a sleep specialist before stopping treatment entirely is important, since untreated sleep apnea carries risks for cardiovascular health, metabolic function, and daytime functioning.

What is positional therapy and when is it used for sleep apnea?

Positional therapy is a non-invasive approach for people whose obstructive sleep apnea occurs primarily or exclusively when sleeping on their back, a pattern called positional or supine-dependent OSA. It works by training or encouraging the sleeper to remain on their side throughout the night. Methods include specially designed positional devices worn around the chest or waist, vibrating wearables that alert the sleeper when they roll onto their back, and older low-tech approaches such as sewing a tennis ball into the back of a sleep shirt. Positional therapy is most useful for mild to moderate positional OSA. A sleep study can confirm whether your apnea is significantly worse in the supine position before this approach is tried as a primary treatment.

How do mandibular advancement devices work for sleep apnea?

A mandibular advancement device is a custom-fitted oral appliance that holds the lower jaw, or mandible, slightly forward during sleep. This forward repositioning of the jaw helps keep the tongue and soft tissue at the back of the throat from collapsing into the upper airway, reducing obstructive apnea events and snoring. Mandibular advancement devices are generally worn nightly and adjusted incrementally over several weeks to find the position that provides the best balance of symptom control and jaw comfort. Side effects can include jaw soreness, tooth sensitivity, and changes in bite alignment over time, particularly with long-term use. A dental sleep medicine provider typically fits and monitors these devices.

What is hypoglossal nerve stimulation and how does it treat sleep apnea?

Hypoglossal nerve stimulation is an implantable treatment for moderate to severe obstructive sleep apnea in patients who have not responded to or cannot tolerate CPAP therapy. The Inspire device is the most widely known system approved by the Food and Drug Administration in the United States. A small generator is implanted under the skin of the chest, and a lead connects to the hypoglossal nerve, which controls tongue movement. During sleep, the device senses breathing patterns and delivers mild electrical stimulation to the nerve, causing the tongue to move slightly forward and keeping the upper airway open. Clinical results have shown meaningful reductions in the apnea-hypopnea index in appropriately selected patients. Eligibility requires specific anatomical and severity criteria assessed through drug-induced sleep endoscopy and other evaluations.

What is expiratory positive airway pressure and how does it compare to CPAP?

Expiratory positive airway pressure, or EPAP, uses small disposable devices placed over the nostrils that create resistance during exhalation. This resistance generates pressure that helps keep the airway open through the subsequent inhalation. EPAP devices such as Provent Therapy and Bongo Rx are mask-free and require no machine or electricity, making them more portable and less intrusive than CPAP. EPAP is generally most effective for mild to moderate obstructive sleep apnea. It does not deliver continuous pressure during inhalation the way a CPAP machine does, so it may not adequately manage more severe apnea. A sleep specialist can advise whether EPAP is a suitable option based on your sleep study results and individual anatomy.

What upper airway surgeries are available for sleep apnea?

Several surgical procedures target different parts of the upper airway to reduce obstruction in obstructive sleep apnea. Uvulopalatopharyngoplasty removes or repositions tissue from the soft palate, uvula, and throat. Barbed reposition pharyngoplasty and lateral pharyngoplasty address the lateral pharyngeal wall muscles and velopharyngeal area. Maxillomandibular advancement repositions the jaw bones to structurally enlarge the airway. Tonsillectomy is often effective when enlarged tonsils are a primary cause of obstruction. Nasal procedures such as septoplasty and turbinate reduction address nasal airflow. An otolaryngologist or ENT specialist, often guided by drug-induced sleep endoscopy findings, can identify which anatomical sites are most likely contributing to airway obstruction and whether surgery is appropriate.

Can lifestyle changes alone manage sleep apnea without other treatments?

Lifestyle changes can meaningfully reduce obstructive sleep apnea severity in some people, particularly when obesity, alcohol use, sedative medication, or sleep position are contributing factors. Weight loss is among the most clinically supported lifestyle interventions, with research showing that significant weight reduction can lower the apnea-hypopnea index. Avoiding alcohol and sedatives before sleep, treating nasal congestion, sleeping on your side, and maintaining consistent sleep habits can all support better airway function. However, lifestyle changes alone rarely eliminate sleep apnea entirely in people with moderate to severe OSA or significant anatomical airway obstruction. They work best as part of a broader, personalised treatment plan developed with a sleep specialist rather than as a standalone approach for significant sleep-disordered breathing.

What is myofunctional therapy and can it help with sleep apnea?

Myofunctional therapy involves targeted exercises for the muscles of the tongue, throat, and face that support the upper airway. The goal is to improve muscle tone and positioning so that the airway is less prone to collapse during sleep. Research, including studies cited by the American Academy of Sleep Medicine, has shown that oropharyngeal exercises can reduce snoring and apnea-hypopnea index scores in adults with mild to moderate obstructive sleep apnea. Myofunctional therapy is typically delivered by a trained speech-language pathologist or myofunctional therapist and requires consistent daily practice over several weeks to months. It is not considered a standalone treatment for severe sleep apnea but may complement other approaches such as oral appliance therapy or lifestyle modifications.

What is the safest non-CPAP treatment for sleep apnea?

No single treatment is universally the safest because each option carries different considerations depending on a person's health, anatomy, and apnea severity. Non-invasive options such as positional therapy, oral appliance therapy, and lifestyle modifications generally carry fewer procedural risks than surgery or implantable devices. Oral appliances are widely used and well tolerated by many patients, though jaw discomfort and bite changes can occur with long-term use. Surgical approaches and hypoglossal nerve stimulation involve procedural risks including infection, pain, and in rare cases complications specific to the technique. A sleep specialist and, where relevant, a surgeon or ENT specialist can help weigh the benefits and risks of each option against your individual health profile and apnea severity.

Does health insurance cover oral appliances or CPAP alternatives for sleep apnea?

Insurance coverage for CPAP alternatives such as oral appliances and surgical procedures varies significantly by plan, provider, and diagnosis. Many private insurers cover oral appliance therapy when prescribed by a licensed provider and supported by a qualifying sleep study. Hypoglossal nerve stimulation such as Inspire therapy has Medicare and many private insurance approvals for eligible patients, though prior authorisation requirements often apply. Surgical procedures may be covered when deemed medically necessary. Coverage decisions depend on your specific plan terms, your documented apnea severity, and the documentation your provider submits. It is important to contact your insurer directly and confirm coverage before proceeding with any treatment.

Can I use HSA or FSA funds for CPAP alternative treatments?

Yes, health savings account and flexible spending account funds can generally be used to pay for qualified medical expenses related to sleep apnea treatment, including oral appliances, CPAP equipment and supplies, sleep studies, and physician-prescribed treatments. Eligible expenses typically require a diagnosis or prescription from a licensed healthcare provider. Specific eligibility depends on your plan administrator and the nature of the expense, so confirming with your HSA or FSA administrator before purchasing is advisable. For members of Dumbo Health, all membership plans are HSA and FSA eligible, and the $149 at-home sleep apnea test is available as a cash-pay option with no insurance required. You can compare sleep longevity plans and pricing to find the right fit for your needs.

What is drug-induced sleep endoscopy and why does it matter for sleep apnea surgery planning?

Drug-induced sleep endoscopy, sometimes abbreviated as DISE, is a diagnostic procedure in which a patient is lightly sedated to simulate the muscle relaxation of natural sleep while a physician uses a small flexible camera to visualise the upper airway and identify where and how obstruction occurs. The information gathered helps surgeons and sleep specialists choose the most targeted surgical approach or determine whether a patient is an appropriate candidate for hypoglossal nerve stimulation. Without this assessment, surgery may address the wrong anatomical site and produce limited results. An otolaryngologist or sleep surgeon typically performs the procedure and reviews findings alongside the patient's sleep study results when developing a personalised treatment plan.

How does sleep apnea affect biological aging and long-term health?

Untreated obstructive sleep apnea is associated with increased cardiovascular risk, metabolic disruption, elevated inflammatory markers, and impaired hormonal regulation, all of which may contribute to accelerated biological aging. Repeated overnight oxygen desaturation, sleep fragmentation, and chronic sleep deprivation place sustained stress on the body's repair and regulatory systems. Research published through institutions such as the NIH has linked untreated sleep apnea to higher rates of heart disease, type 2 diabetes, hypertension, and cognitive decline over time. Tracking biomarkers such as hs-CRP, HbA1c, cortisol, and cardiovascular markers can provide insight into how sleep disruption may be affecting key biological processes. Dumbo Health's sleep longevity biomarker testing is designed to help people understand how sleep health may be influencing their biological age over time.

How can I get an at-home sleep apnea test without a CPAP referral or insurance requirement?

An at-home sleep apnea test, also called a home sleep apnea test or HSAT, can be ordered without a traditional insurance-based referral through cash-pay platforms. Dumbo Health offers an FDA-cleared at-home sleep apnea test for $149 as a one-time purchase, separate from any membership plan. The device is used for one night at home, and a physician diagnosis is typically available within 48 hours of the completed test. The test is available in Florida, Texas, Virginia and Maryland. If sleep apnea is confirmed, a personalised treatment plan can be developed, which may include CPAP therapy or an alternative treatment pathway depending on your results and clinical picture. You can take the free sleep quiz to help decide whether home sleep testing may be a reasonable next step for you.

When should I speak with a healthcare professional rather than trying a CPAP alternative on my own?

You should speak with a qualified healthcare professional before starting, stopping, or switching any sleep apnea treatment. Self-managing sleep apnea without clinical guidance carries real risks, since untreated or undertreated moderate to severe obstructive sleep apnea is associated with serious cardiovascular, metabolic, and neurological consequences. A sleep specialist can confirm your diagnosis through a proper sleep study, assess the severity of your apnea-hypopnea index, identify the anatomical or physiological causes of your airway obstruction, and recommend a treatment plan matched to your clinical profile. If you experience severe daytime sleepiness, witnessed breathing pauses during sleep, chest pain, or other urgent symptoms, seek medical care promptly rather than waiting for a scheduled appointment.